BFLY vs IOVA
Butterfly Network, Inc. vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
BFLY
Butterfly Network, Inc.
67
Buy
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | BFLY | IOVA |
|---|
| AI Score |
67
|
67
|
| Price |
$9.36
|
$6.49
|
| P/E Ratio |
-32.38×
|
-9.27×
|
| ROE |
-39.3%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
51.1%
|
116.3%
|
| Debt / Equity |
0.10×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
66.4
|
79.2
|
| Beta |
2.084
|
0.701
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for BFLY versus IOVA.
The committee scores are tied.
BFLY and IOVA both score 67/100.
BFLY Committee View
67% agreement
6 analysts
The primary driver is revenue growing 28.1% yoy -- genuine top-line momentum. The main limiting factor is roe of only -38.4% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 28.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -38.4% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 52.6% signals elevated volatility — Risk
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical